Ares Capital Corp. (ARCC)

Ares Capital's stock has been drifting higher on the back of analyst support, even as its reported profits have lagged expectations. UBS upgraded the stock to Buy from Neutral on October 29, 2026, two days after the company's October 27 earnings report, which came in at $0.46 per share against a $0.48 estimate. The stock fell 0.54% in the first session after that report, and the market has so far looked past the miss. Shares sit 1.58% above their 50-day average and 2.46% above their 200-day average, and the trend is up. The question for investors is whether analyst conviction can hold up if quarterly earnings keep missing and revenue keeps shrinking.

Analysts remain firmly supportive. Of 13 analysts with a current rating, 12 rate the stock buy or strong buy, one holds, and none sell, and the consensus is Strong Buy. That is a shift from three months ago, when 11 of 14 ratings were buy. The most recent move came from UBS, which upgraded the stock to Buy from Neutral on October 29, 2026, after previously keeping a Neutral rating on September 1, 2026. Wells Fargo went the other way on June 12, 2026, when it downgraded the stock to Equal-Weight from Overweight.

The business is the weak point in the picture. The October 27, 2026 report showed adjusted EPS of $0.46 against an estimate of $0.48, a miss of 4.17%, and the stock fell 0.54% in the next session. None of the last seven reports beat the EPS estimate, with two matching it exactly and the rest missing. Reported profit is healthy, with a net margin of 81.8%, but return on equity of 6.19% is below the sector median of 13.8%, and debt-to-equity stands at 1.08.

At a trailing P/E of 15.86, the stock trades 3.9% below the sector median P/E of 16.5, which is broadly in line with peers. The trailing dividend yield is 9.88% on an annual dividend of $1.92 per share, which is the main reason many holders stay with the stock. The dividend is the core of the return case, and it depends on earnings that have been missing estimates.

Insiders have been buyers rather than sellers. Over the last 18 months, there were six insider purchases worth $1.0M in total and no insider sales. On the chart, the 14-day RSI of 57.7 is in the neutral zone, and the MACD line is positive, which supports the uptrend. The stock is up 4.71% over one month and 2.24% over one week, although it is down 4.21% over the past year.

The base case is that ARCC trades in a narrow range near its moving averages while the business goes through a slower patch. Analysts expect earnings per share to shrink 6.4% this fiscal year, to $1.88, before growing 3.2% next year to $1.94, so the recovery case depends on the company returning to growth in 2027. Analysts' median 12-month target is $21.00, with a range of $20.00 to $23.00, which sits 18.3% above the current price of $19.44. The bearish case is that revenue keeps shrinking and misses continue, which would test the 50-day and 200-day averages and weaken the case for the Buy ratings. A stronger quarter in which EPS meets or beats estimates would support the upgrade thesis. Simulations from past volatility are not forecasts, and the stock's 1.28% typical daily move gives a sense of normal day-to-day swings.

Support sits first at the 50-day simple moving average of $19.13, which is the nearest level below the price. Next is the 20-day exponential moving average at $19.05, followed by the 200-day simple moving average at $18.97, which sits close enough to act as a single support zone. The 52-week low of $17.40 is the deeper floor. On the upside, the nearest resistance is the 52-week high of $21.14, which the stock would need to clear to set a new high. Analysts' lowest target of $20.00 and median target of $21.00 sit between the price and that high.